VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q71715527 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235826.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q71715527‏
024 ‎‡a 0000-0003-4764-6290‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q71715527‏
100 0 ‎‡a ব্রায়ান জোন্স‏ ‎‡9 bn‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Bryan Jones‏ ‎‡c researcher (ORCID 0000-0003-4764-6290)‏ ‎‡9 en‏
400 0 ‎‡a Bryan Jones‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's A strategy for testing the suitability of cysteine replacements in dihydrofolate reductase from Escherichia coli.‏
670 ‎‡a Author's A Strategy for Testing the Suitability of Cysteine Replacements in Dihydrofolate Reductase from Escherichia coli1‏
670 ‎‡a Author's An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential.‏
670 ‎‡a Author's Binding of the catabolite repressor protein CcpA to its DNA target is regulated by phosphorylation of its corepressor HPr‏
670 ‎‡a Author's Development of a high-throughput solubility screening assay for use in antibody discovery‏
670 ‎‡a Author's Development of nonpolar surfaces in the folding of Escherichia coli dihydrofolate reductase detected by 1-anilinonaphthalene-8-sulfonate binding‏
670 ‎‡a Author's Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease‏
670 ‎‡a Author's Distinct functions of activated protein C differentially attenuate acute kidney injury.‏
670 ‎‡a Author's Engineering the proteolytic specificity of activated protein C improves its pharmacological properties‏
670 ‎‡a Author's Local and global dynamics during the folding of Escherichia coli dihydrofolate reductase by time-resolved fluorescence spectroscopy‏
670 ‎‡a Author's LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection‏
670 ‎‡a Author's Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial‏
670 ‎‡a Author's Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting‏
670 ‎‡a Author's Phosphorylation on histidine is accompanied by localized structural changes in the phosphocarrier protein, HPr from Bacillus subtilis.‏
670 ‎‡a Author's Probing the folding mechanism of a leucine zipper peptide by stopped-flow circular dichroism spectroscopy‏
670 ‎‡a Author's RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery.‏
670 ‎‡a Author's Solvent exchange rates of side-chain amide protons in proteins.‏
670 ‎‡a Author's The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates‏
909 ‎‡a (orcid) 0000000347646290‏ ‎‡9 1‏
919 ‎‡a bindingofthecataboliterepressorproteinccpatoitsdnatargetisregulatedbyphosphorylationofitscorepressorhpr‏ ‎‡A Binding of the catabolite repressor protein CcpA to its DNA target is regulated by phosphorylation of its corepressor HPr‏ ‎‡9 1‏
919 ‎‡a developmentofahighthroughputsolubilityscreeningassayforuseinantibodydiscovery‏ ‎‡A Development of a high-throughput solubility screening assay for use in antibody discovery‏ ‎‡9 1‏
919 ‎‡a developmentofnonpolarsurfacesinthefoldingofescherichiacolidihydrofolatereductasedetectedby1anilinonaphthalene8sulfonatebinding‏ ‎‡A Development of nonpolar surfaces in the folding of Escherichia coli dihydrofolate reductase detected by 1-anilinonaphthalene-8-sulfonate binding‏ ‎‡9 1‏
919 ‎‡a developmentoftibulizumabatetravalentbispecificantibodytargetingbaffandil17aforthetreatmentofautoimmunedisease‏ ‎‡A Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease‏ ‎‡9 1‏
919 ‎‡a distinctfunctionsofactivatedprotein100differentiallyattenuateacutekidneyinjury‏ ‎‡A Distinct functions of activated protein C differentially attenuate acute kidney injury.‏ ‎‡9 1‏
919 ‎‡a engineeringtheproteolyticspecificityofactivatedprotein100improvesitspharmacologicalproperties‏ ‎‡A Engineering the proteolytic specificity of activated protein C improves its pharmacological properties‏ ‎‡9 1‏
919 ‎‡a localandglobaldynamicsduringthefoldingofescherichiacolidihydrofolatereductasebytimeresolvedfluorescencespectroscopy‏ ‎‡A Local and global dynamics during the folding of Escherichia coli dihydrofolate reductase by time-resolved fluorescence spectroscopy‏ ‎‡9 1‏
919 ‎‡a lycov555arapidlyisolatedpotentneutralizingantibodyprovidesprotectioninanonhumanprimatemodelofsarscov2infection‏ ‎‡A LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection‏ ‎‡9 1‏
919 ‎‡a multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephase2multicladeab100hiv1dnaprimerad5boostvaccinetrial‏ ‎‡A Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial‏ ‎‡9 1‏
919 ‎‡a myostatinneutralizationresultsinpreservationofmusclemassandstrengthinpreclinicalmodelsoftumorinducedmusclewasting‏ ‎‡A Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting‏ ‎‡9 1‏
919 ‎‡a phosphorylationonhistidineisaccompaniedbylocalizedstructuralchangesinthephosphocarrierproteinhprfrombacillussubtilis‏ ‎‡A Phosphorylation on histidine is accompanied by localized structural changes in the phosphocarrier protein, HPr from Bacillus subtilis.‏ ‎‡9 1‏
919 ‎‡a probingthefoldingmechanismofaleucinezipperpeptidebystoppedflowcirculardichroismspectroscopy‏ ‎‡A Probing the folding mechanism of a leucine zipper peptide by stopped-flow circular dichroism spectroscopy‏ ‎‡9 1‏
919 ‎‡a rampedupnmrmultiplexednmrbasedscreeningfordrugdiscovery‏ ‎‡A RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery.‏ ‎‡9 1‏
919 ‎‡a solventexchangeratesofsidechainamideprotonsinproteins‏ ‎‡A Solvent exchange rates of side-chain amide protons in proteins.‏ ‎‡9 1‏
919 ‎‡a neutralizingantibodylycov555protectsagainstsarscov2infectioninnonhumanprimates‏ ‎‡A The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates‏ ‎‡9 1‏
919 ‎‡a strategyfortestingthesuitabilityofcysteinereplacementsindihydrofolatereductasefromescherichiacoli‏ ‎‡A A strategy for testing the suitability of cysteine replacements in dihydrofolate reductase from Escherichia coli.‏ ‎‡9 1‏
919 ‎‡a strategyfortestingthesuitabilityofcysteinereplacementsindihydrofolatereductasefromescherichiacoli1‏ ‎‡A A Strategy for Testing the Suitability of Cysteine Replacements in Dihydrofolate Reductase from Escherichia coli1‏ ‎‡9 1‏
919 ‎‡a engineeredhumanfollistatinvariantinsightsintothepharmacokineticandpharmocodynamicrelationshipsofanovelmoleculewithbroadtherapeuticpotential‏ ‎‡A An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 DNB|1141803747‏
996 ‎‡2 NTA|189146729‏
996 ‎‡2 DNB|132220296‏
996 ‎‡2 PLWABN|9810634186305606‏
996 ‎‡2 PTBNP|1859307‏
996 ‎‡2 BIBSYS|90143228‏
996 ‎‡2 NTA|181458888‏
996 ‎‡2 ISNI|0000000042824930‏
996 ‎‡2 BNC|981058609052406706‏
996 ‎‡2 J9U|987007271598705171‏
996 ‎‡2 BNF|13517705‏
996 ‎‡2 LC|n 81107353‏
996 ‎‡2 RERO|A013601257‏
996 ‎‡2 ISNI|0000000053884197‏
996 ‎‡2 ISNI|0000000114999159‏
996 ‎‡2 NTA|096894296‏
996 ‎‡2 BIBSYS|7030024‏
996 ‎‡2 SUDOC|243680392‏
996 ‎‡2 NUKAT|n 2015053764‏
996 ‎‡2 SUDOC|242185932‏
996 ‎‡2 NUKAT|n 97090821‏
996 ‎‡2 SUDOC|146467582‏
996 ‎‡2 SUDOC|270893016‏
996 ‎‡2 LNB|LNC10-000005663‏
996 ‎‡2 BNE|XX5325501‏
996 ‎‡2 NTA|139390456‏
996 ‎‡2 ISNI|0000000043911681‏
996 ‎‡2 NUKAT|n 2007002786‏
996 ‎‡2 ISNI|0000000073075813‏
996 ‎‡2 DNB|121596028‏
996 ‎‡2 LC|no2012017497‏
996 ‎‡2 BNF|12698294‏
996 ‎‡2 DNB|1030240744‏
996 ‎‡2 SUDOC|242243118‏
996 ‎‡2 ISNI|0000000050801093‏
996 ‎‡2 ISNI|0000000038837237‏
996 ‎‡2 NTA|069330212‏
996 ‎‡2 LC|n 88646824‏
996 ‎‡2 BIBSYS|99071059‏
996 ‎‡2 LC|n 2001147387‏
996 ‎‡2 LC|n 2001147386‏
996 ‎‡2 LC|n 95079237‏
996 ‎‡2 CAOONL|ncf10237037‏
996 ‎‡2 ISNI|0000000114483232‏
996 ‎‡2 LC|n 88660132‏
996 ‎‡2 ISNI|0000000043322422‏
996 ‎‡2 ISNI|0000000073249983‏
996 ‎‡2 ISNI|000000003898195X‏
996 ‎‡2 NUKAT|n 2011241548‏
996 ‎‡2 CAOONL|ncf11556176‏
996 ‎‡2 RERO|A027345541‏
996 ‎‡2 J9U|987007358853905171‏
996 ‎‡2 NUKAT|n 2006106828‏
996 ‎‡2 ISNI|0000000042466125‏
996 ‎‡2 NII|DA07952331‏
996 ‎‡2 DNB|1233929216‏
996 ‎‡2 DNB|1242121285‏
996 ‎‡2 DNB|139917446‏
996 ‎‡2 CAOONL|ncf10721771‏
996 ‎‡2 DNB|119302225‏
996 ‎‡2 BNF|12385245‏
996 ‎‡2 ISNI|0000000072874330‏
996 ‎‡2 BNF|12874105‏
996 ‎‡2 ISNI|0000000083519449‏
996 ‎‡2 LC|no2017163036‏
996 ‎‡2 LC|no2009185130‏
996 ‎‡2 NUKAT|n 97035317‏
996 ‎‡2 LC|nb2007024756‏
996 ‎‡2 LC|no2006008908‏
996 ‎‡2 ISNI|0000000077366140‏
996 ‎‡2 BLBNB|000252019‏
996 ‎‡2 LC|n 2007036655‏
996 ‎‡2 DNB|1035759764‏
996 ‎‡2 ISNI|000000038473429X‏
996 ‎‡2 NTA|157136310‏
996 ‎‡2 CAOONL|ncf10364711‏
996 ‎‡2 LC|nb2016021798‏
996 ‎‡2 ISNI|0000000030287605‏
996 ‎‡2 LC|no2016165310‏
996 ‎‡2 NII|DA13349028‏
996 ‎‡2 LC|n 85235236‏
996 ‎‡2 CAOONL|ncf10013009‏
996 ‎‡2 ISNI|0000000044986431‏
996 ‎‡2 SIMACOB|44682851‏
996 ‎‡2 LC|no2009187337‏
996 ‎‡2 ISNI|0000000040512992‏
996 ‎‡2 PLWABN|9810560847005606‏
996 ‎‡2 DNB|1027273483‏
996 ‎‡2 PLWABN|9810569318305606‏
996 ‎‡2 BIBSYS|9058234‏
996 ‎‡2 LC|n 50040337‏
996 ‎‡2 LC|no2009076667‏
996 ‎‡2 ISNI|0000000055506309‏
996 ‎‡2 DNB|1044270128‏
996 ‎‡2 NTA|067537588‏
996 ‎‡2 LC|n 2014040326‏
996 ‎‡2 LC|no 90025123‏
996 ‎‡2 BNF|17774140‏
996 ‎‡2 ISNI|0000000066901195‏
996 ‎‡2 NII|DA07257832‏
996 ‎‡2 BNC|981058516872406706‏
996 ‎‡2 PLWABN|9813923196505606‏
996 ‎‡2 CAOONL|ncf10728244‏
996 ‎‡2 NTA|314107754‏
996 ‎‡2 LC|n 87133256‏
996 ‎‡2 ISNI|0000000079922948‏
996 ‎‡2 LC|n 82009220‏
996 ‎‡2 BIBSYS|90805384‏
996 ‎‡2 BLBNB|001474790‏
996 ‎‡2 SUDOC|055321224‏
996 ‎‡2 ISNI|0000000497699064‏
996 ‎‡2 DNB|1073263290‏
996 ‎‡2 LC|nr 99013301‏
996 ‎‡2 NTA|153763957‏
996 ‎‡2 N6I|vtls002141734‏
996 ‎‡2 NDL|00620893‏
996 ‎‡2 NKC|hka2010554648‏
996 ‎‡2 BLBNB|001123034‏
996 ‎‡2 SUDOC|060281057‏
996 ‎‡2 LC|n 2012013718‏
996 ‎‡2 LC|nb2004025307‏
996 ‎‡2 LC|n 99282429‏
996 ‎‡2 NKC|mub2016900696‏
996 ‎‡2 LC|n 2022002988‏
996 ‎‡2 ISNI|000000004074788X‏
996 ‎‡2 NUKAT|n 2016224791‏
996 ‎‡2 LC|no2016146094‏
996 ‎‡2 J9U|987007388382205171‏
996 ‎‡2 ISNI|0000000409413872‏
996 ‎‡2 LIH|LNB:C_v_X_n_;=CP‏
996 ‎‡2 ISNI|000000012358211X‏
996 ‎‡2 LC|nb2003009374‏
996 ‎‡2 RERO|A027221440‏
996 ‎‡2 LC|nb2004304943‏
996 ‎‡2 LC|no2015163517‏
996 ‎‡2 PLWABN|9810586690705606‏
996 ‎‡2 ISNI|0000000114465659‏
996 ‎‡2 ISNI|0000000042622669‏
996 ‎‡2 DNB|1050942272‏
996 ‎‡2 LC|nb2008025248‏
996 ‎‡2 LIH|LNB:BTEB;=_w_C‏
996 ‎‡2 NTA|412412454‏
996 ‎‡2 NYNYRILM|292566‏
996 ‎‡2 BIBSYS|90284988‏
996 ‎‡2 ISNI|0000000035781880‏
996 ‎‡2 BNF|16171821‏
996 ‎‡2 BIBSYS|90175113‏
996 ‎‡2 BNF|12681950‏
996 ‎‡2 LC|no2018136443‏
996 ‎‡2 NUKAT|n 00043513‏
996 ‎‡2 LC|n 86038515‏
996 ‎‡2 BNF|15067429‏
996 ‎‡2 LC|n 99043647‏
996 ‎‡2 LC|no2007155409‏
996 ‎‡2 LC|no2013017743‏
996 ‎‡2 J9U|987007442434005171‏
996 ‎‡2 NUKAT|n 2014009766‏
996 ‎‡2 RERO|A003429426‏
996 ‎‡2 RERO|A003429425‏
996 ‎‡2 RERO|A003429424‏
996 ‎‡2 RERO|A003429423‏
996 ‎‡2 NUKAT|n 2010192052‏
996 ‎‡2 LC|nb 99101207‏
996 ‎‡2 RERO|A003429429‏
996 ‎‡2 ISNI|0000000042434748‏
996 ‎‡2 NKC|uk2014845909‏
996 ‎‡2 BNF|14485690‏
996 ‎‡2 LC|n 87138981‏
996 ‎‡2 NTA|344691004‏
996 ‎‡2 LC|n 2005057615‏
996 ‎‡2 ISNI|0000000074553610‏
996 ‎‡2 J9U|987007610293505171‏
996 ‎‡2 BNF|14587311‏
996 ‎‡2 ISNI|0000000115820712‏
996 ‎‡2 LNB|LNC10-000062924‏
996 ‎‡2 SUDOC|280422067‏
996 ‎‡2 PLWABN|9810582373905606‏
996 ‎‡2 SUDOC|034645632‏
996 ‎‡2 LC|n 2018046409‏
996 ‎‡2 ISNI|0000000402225588‏
996 ‎‡2 BNF|13607502‏
996 ‎‡2 PLWABN|9812076284105606‏
996 ‎‡2 ISNI|0000000067077855‏
996 ‎‡2 CAOONL|ncf10358370‏
996 ‎‡2 SUDOC|15188790X‏
996 ‎‡2 ISNI|0000000368485094‏
996 ‎‡2 LC|nb2003063585‏
996 ‎‡2 SUDOC|225341492‏
996 ‎‡2 PLWABN|9810672718205606‏
996 ‎‡2 NTA|075060906‏
996 ‎‡2 DNB|1030241406‏
996 ‎‡2 LC|n 99256684‏
996 ‎‡2 LC|n 95910893‏
996 ‎‡2 LC|no2024115548‏
996 ‎‡2 LC|nb2013018010‏
996 ‎‡2 LC|nb2016021764‏
996 ‎‡2 DNB|103705119X‏
996 ‎‡2 ISNI|0000000367667072‏
996 ‎‡2 BIBSYS|90556157‏
996 ‎‡2 ISNI|0000000109156720‏
996 ‎‡2 SUDOC|070117527‏
996 ‎‡2 LC|n 95802850‏
996 ‎‡2 NII|DA01247417‏
996 ‎‡2 ISNI|0000000107805950‏
996 ‎‡2 LC|n 96099804‏
996 ‎‡2 BNF|16592058‏
996 ‎‡2 NII|DA00592497‏
996 ‎‡2 ISNI|0000000500877336‏
996 ‎‡2 CAOONL|ncf11364369‏
996 ‎‡2 RERO|A012393148‏
996 ‎‡2 LC|no2010128688‏
996 ‎‡2 LC|n 93801273‏
996 ‎‡2 RERO|A013601230‏
996 ‎‡2 CAOONL|ncf10503270‏
996 ‎‡2 DNB|121600270‏
996 ‎‡2 NSK|000379199‏
996 ‎‡2 ISNI|0000000054500570‏
996 ‎‡2 BIBSYS|7015283‏
996 ‎‡2 LC|n 85267141‏
996 ‎‡2 NUKAT|n 2004005406‏
996 ‎‡2 SUDOC|032915454‏
996 ‎‡2 BIBSYS|90784966‏
996 ‎‡2 PLWABN|9810585332905606‏
996 ‎‡2 J9U|987007581662505171‏
996 ‎‡2 SUDOC|230995888‏
996 ‎‡2 RERO|A027345516‏
996 ‎‡2 DNB|1046825410‏
996 ‎‡2 BNF|13981721‏
996 ‎‡2 NUKAT|n 2005111512‏
996 ‎‡2 CAOONL|ncf11071494‏
996 ‎‡2 DNB|132409135‏
996 ‎‡2 LC|n 2006017028‏
996 ‎‡2 BAV|495_196602‏
996 ‎‡2 BNF|13564572‏
996 ‎‡2 NLA|000035175540‏
996 ‎‡2 SUDOC|25255986X‏
996 ‎‡2 B2Q|0000284438‏
996 ‎‡2 LC|n 2005075746‏
996 ‎‡2 BNF|12373291‏
996 ‎‡2 BIBSYS|90971798‏
996 ‎‡2 SUDOC|133030997‏
996 ‎‡2 DNB|1218984058‏
996 ‎‡2 LC|n 2009070254‏
996 ‎‡2 BNF|18151005‏
996 ‎‡2 ISNI|0000000023740707‏
996 ‎‡2 ISNI|0000000395373303‏
996 ‎‡2 LNB|LNC10-000100153‏
996 ‎‡2 NSK|000689787‏
996 ‎‡2 ISNI|0000000366953712‏
996 ‎‡2 NUKAT|n 2002098852‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏